Sera Prognostics Reports Q3 2025 Financial Results

Sera Prognostics, Inc. ( (SERA) ) has released its Q3 earnings. Here is a breakdown of the information Sera Prognostics, Inc. presented to its investors.

Sera Prognostics, Inc., a health diagnostics company headquartered in Salt Lake City, Utah, specializes in precision pregnancy care by offering innovative biomarker information to improve maternal and neonatal health. The company has recently reported its financial results for the third quarter of 2025, highlighting significant progress in payer initiatives and strategic leadership appointments.

In the third quarter of 2025, Sera Prognostics made notable advancements, including launching a Medicaid pilot in Nevada and engaging with payers across thirteen states. The company is poised to publish full study results of its PRIME study, which is expected to demonstrate the health economic benefits of its PreTRM Test. Additionally, Sera has strengthened its leadership team with the appointments of Dr. Tiffany Inglis as Chief Medical Officer and Marisol Urbano as Head of Commercial Operations.

Financially, Sera Prognostics reported a revenue of $16,000 for the third quarter of 2025, a decrease from $29,000 in the same period of 2024. Operating expenses slightly increased to $9.0 million, while the net loss for the quarter was $7.8 million, a slight improvement from the previous year’s $7.9 million loss. The company holds cash and equivalents of approximately $102.4 million, expected to support its operations through significant milestones until 2028.

Looking ahead, Sera Prognostics is focused on driving adoption of its PreTRM Test and expanding its market engagement. The company is actively pursuing broader coverage at the employer, plan, and state levels to transform prenatal care and deliver long-term value for shareholders. With ongoing discussions and strategic initiatives, Sera is well-positioned to make a meaningful impact in the maternal and neonatal health sector.